• LAST PRICE
    12.0199
  • TODAY'S CHANGE (%)
    Trending Down-0.2401 (-1.9584%)
  • Bid / Lots
    11.8800/ 2
  • Ask / Lots
    12.0200/ 3
  • Open / Previous Close
    12.0100 / 12.2600
  • Day Range
    Low 11.6300
    High 12.1600
  • 52 Week Range
    Low 4.3000
    High 17.8900
  • Volume
    75,908
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 12.26
TimeVolumeDYN
09:32 ET1066212.16
09:34 ET20012.13
09:38 ET19612.07
09:39 ET12112.0306
09:43 ET1903811.92
09:45 ET11011.895
09:48 ET1970011.85
09:50 ET10011.845
09:52 ET42511.71
09:59 ET20011.74
10:01 ET30011.82
10:03 ET35011.69
10:14 ET30011.76
10:21 ET10011.83
10:24 ET20011.78
10:37 ET1670011.865
10:42 ET10011.79
10:44 ET70011.83
10:48 ET120011.92
10:53 ET10012.015
10:55 ET10011.945
10:57 ET10012.0199
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesDYN
Dyne Therapeutics Inc
618.6M
-3.4x
---
United StatesOCGN
Ocugen Inc
612.9M
-8.2x
---
United StatesKOD
Kodiak Sciences Inc
649.4M
-1.6x
---
United StatesNUVB
Nuvation Bio Inc
587.1M
-5.8x
---
United StatesAVTE
Aerovate Therapeutics Inc
593.2M
-16.3x
---
United StatesIMVT
Immunovant Inc
636.5M
-3.4x
---
As of 2022-08-19

Company Information

Dyne Therapeutics Inc. is a muscle disease company. The Company is focused on advancing therapeutics for patients with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that it has designed to target the genetic basis of the disease. Using its FORCE platform, the Company is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker. In addition, It plans to expand its portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases.

Contact Information

Headquarters
1560 Trapelo RoadWALTHAM, MA, United States 02451
Phone
781-786-8230
Fax
781-786-8866

Executives

Independent Chairman of the Board
Jason Rhodes
President, Chief Executive Officer, Director
Joshua Brumm
Chief Operating Officer
Susanna High
Senior Vice President - Business Development
Jonathan McNeill
Chief Scientific Officer
Oxana Beskrovnaya

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$618.6M
Revenue (TTM)
$0.00
Shares Outstanding
51.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-3.54
Book Value
$7.14
P/E Ratio
-3.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.